Chaperonin Peptide Dosing at Relapse Onset for ARDS Remission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies for inflammatory conditions using chaperonin peptides require continuous dosing to maintain therapeutic effects, leading to compliance issues and increased drug burden, with no respite for patients.
Innovation Solution
Administering chaperonin peptides intermittently at the onset of a relapse provides a disease-modifying effect, allowing for remission without the need for continuous dosing, using specific peptide sequences that can be administered in one or multiple doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chaperonin peptides are administered continuously to maintain therapeutic effects, then the therapeutic efficacy is improved, but patient compliance deteriorates and drug burden increases
Solution Approach 1:
The patent applies periodic action by administering chaperonin peptides intermittently rather than continuously. The peptide is given at the onset of relapse to induce remission, then stopped to allow the body to clear it naturally. This periodic dosing strategy maintains therapeutic efficacy while significantly improving patient compliance and reducing drug burden, as patients experience remission periods without medication.
2Duration of action of moving object
If chaperonin peptides are administered continuously to maintain detectable levels in blood plasma, then the therapeutic effect is maintained, but the treatment duration increases and patient lifestyle is restricted
Solution Approach 1:
The patent applies preliminary action by administering the peptide at the precise moment of relapse onset to preemptively induce remission. This timing strategy allows the peptide to initiate the remission process before symptoms fully develop, then the treatment can be stopped while the remission effect continues to unfold and consolidate over time, reducing overall treatment duration.
Solution Approach 2:
The intermittent dosing schedule allows therapeutic effects to accumulate during treatment periods while providing drug-free intervals that allow natural clearance. This creates a pattern where short treatment bursts produce long-lasting remission effects, improving the ratio of therapeutic benefit to treatment time investment.
3Speed
If chaperonin peptides are administered at higher doses to achieve acute remission, then the remission speed is improved, but the drug burden and potential side effects increase
Solution Approach 1:
By administering the peptide at the precise onset of relapse, the treatment achieves maximum efficacy at lower doses compared to chronic maintenance dosing. The preliminary timing allows the peptide to capitalize on the early inflammatory cascade, achieving remission with minimal effective dosage and thus minimizing drug burden and side effects.
Solution Approach 2:
The patent changes the dosing parameter from continuous low-dose maintenance to intermittent higher-dose acute treatment. This parameter change allows achievement of remission with total cumulative dose optimized for efficacy while minimizing long-term drug burden, as the drug is cleared between dosing intervals rather than accumulating in the system.
Data Source
AI summary
The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.